Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Therapeutics
Home
Therapeutics
Therapeutics
Type here to filter the list
1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER
Favorite
18: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)
Favorite
19: From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up
Favorite
20: Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy
Favorite
21: AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma
Favorite
29: LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Favorite
30: Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study
Favorite